Physician profile
Simon Khagi
NPI 1710121165
$82,525.04
in general payments reported to CMS, 2019-2025
22 companies · $39K in 2025
The $39K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,000 · 2021: $108 · 2022: $14K · 2023: $17K · 2024: $11K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Honoraria: $24K · Consulting Fee: $7,550 · Travel and Lodging: $6,129 · Food and Beverage: $3,617 · Education: $89.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $25,675.00 |
| Honoraria | $23,570.00 |
| Consulting Fee | $7,550.00 |
| Travel and Lodging | $6,129.21 |
| Food and Beverage | $3,616.53 |
| Education | $89.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $80,567.05 | 2020-2025 | Optune Lua (Novottf-200t), Optune, Optune Gio |
| Galvanize Therapeutics, INC | $652.18 | 2024-2025 | Aliya System |
| Gt Medical Technologies, INC | $253.22 | 2022-2023 | Gammatile |
| Servier Pharmaceuticals LLC | $253.11 | 2024-2025 | |
| Zap Surgical Systems, INC. | $201.15 | 2023 | Zap-X Mv Imager, Zap-X Treatment Planning Software, Zap-X Radiosurgery System |
| Insightec,INC | $95.28 | 2025 | Exablate |
| Telix Pharmaceuticals | $84.62 | 2024-2025 | Illuccix |
| Daiichi Sankyo INC. | $84.22 | 2023-2024 | Enhertu |
| Array Biopharma INC | $59.29 | 2025 | Mektovi, Braftovi, Tukysa |
| Tempus Ai, INC | $45.05 | 2024 | |
| Amgen INC. | $32.72 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.50 | 2023 | Alunbrig |
| Jazz Pharmaceuticals INC. | $29.39 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $28.67 | 2023 | Lynparza |
| Coherus Oncology, INC. | $24.96 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.93 | 2024 | |
| Abbvie INC. | $22.69 | 2024 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Integra Lifesciences Corporation | $14.01 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Khagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.